| 发明名称 |
IBRUTINIB COMBINATION THERAPY |
| 摘要 |
Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and second anticancer agents. |
| 申请公布号 |
US2016287592(A1) |
申请公布日期 |
2016.10.06 |
| 申请号 |
US201414778536 |
申请日期 |
2014.04.08 |
| 申请人 |
PHARMACYCLICS LLC ;JANSSEN PHARMACEUTICA NV |
发明人 |
CHANG Betty;BALASUBRAMANIAN Sriram;CROWLEY Richard;KUO Hsu-Ping;HALL Brett;SASSER Kate A.;CASNEUF Tineke;SHAFFER Michael;VERSELE Matthias;LIGTENBERG Willem;DAVIS Cuc |
| 分类号 |
A61K31/519;A61K31/454;A61K31/5383;A61K31/496;A61K31/4439;A61K31/5377;A61K31/395;A61K39/395;A61K31/664;A61K31/704;A61K31/4745;A61K31/573;A61K31/7048;A61K31/7068;A61K31/282;A61K45/06 |
主分类号 |
A61K31/519 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising:
a. Ibrutinib; and b. an anticancer agent, wherein the anticancer agent inhibits Bcl-2; Janus kinase 2 (JAK2); Anaplastic lymphoma kinase (ALK); or heat shock protein 90 (Hsp90), wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone. |
| 地址 |
Sunnyvale CA US |
